Germany Legal Cannabis Market (2025 - 2033) Size, Share & Trends Analysis Report By Source (Hemp, Marijuana), By Derivatives (CBD, THC), By End Use (Industrial Use, Medical Use, Recreational Use), And Segment Forecasts

Germany Legal Cannabis Market Trends

The Germany legal cannabis market size was estimated at USD 2.04 billion in 2024 and is expected to reach USD 9.66 billion by 2033, growing at a CAGR of 18.9% from 2025 to 2033. Factors such as the growing adoption of cannabis for the treatment of chronic diseases, affirmative legal advancements in the country, increasing research activities on its therapeutic use, and growing adoption and introduction of CBD cosmetic products drive market growth. For instance, in September 2023, Cronos Group Inc. launched the medical brand PEACE NATURALS in Germany. In July, the company signed a distribution agreement with Cansativa Group, a distributor of medical cannabis in Germany.

Furthermore, favorable government initiatives and rising demand for CBD-infused products in Germany fuel the market growth. For instance, the general European Union (EU) position has been adopted by Germany, which allows some form of reasonable sale of non-food CBD products as long as they contain no more than 0.2% delta-9 tetrahydrocannabinol (THC). Moreover, Küsten CBD, a German CBD cosmetics company, offers CBD cosmetics, including Cooling gel for accompanying symptoms of muscle tension, osteoarthritis, and bruises; Warming gel for joint pain and back pain; Tattoo/Body Lotion for dry skin prone to acne and neurodermatitis; Body oil/massage oil (Rose Dream) for daily body care, and Facial Fluid (Anti-Aging - Lime) for dry and sensitive skin.

Moreover, rising prevalence of chronic conditions such as diabetes, cancer, and neurological conditions and growing research activities and clinical trials in Germany propel the market growth. For instance, in October 2023, Avextra, a biopharmaceutical company, moved forward with a double-blind Phase 2 clinical trial for the use of Belcanto in the treatment of cancer patients in palliative care. This medicine received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) and the responsible ethics committees, with the first patient expected to be dosed in December 2023.

The presence of several insurance companies in the German healthcare system drives market growth. People can choose between public insurance (GKV) or private insurance (PKV) in Germany. Since January 2017, public health insurers have been mandated to provide coverage for cannabis medication up to 5 ounces, which is more than the legal limit of 3.5 ounces or 100 grams per month. This makes Germany one of the potentially lucrative markets in Europe. The insurance scheme encompasses all cannabis treatments and does not specify the particular medical conditions that are covered. Thus, such factors boost the market growth in the country.

In addition, there is a high demand for various CBD-infused products, such as oil, beauty products, and cannabis extracts, driving the market growth. For instance, in September 2021, Alternative Medical Products Inc., a supplier of cosmetic CBD products to German pharmacies, launched the CBD brand CANAVEX. It is a CBD cosmetic product sold by pharmacists without a doctor's prescription. This formulation contains high-quality CBD sourced from EU-GMP compliant and Germany, organic hemp seed oil and vitamin E.

Factors such as favorable government initiatives, rising awareness regarding therapeutic uses of cannabis, and a growing number of consumers are expected to grow the market during the forecast period. Moreover, the presence of several cannabis testing labs or companies in Germany, such as AZ Biopharm, WESSLING part of ALS Limited, Eurofins Deutschland and Laboratorium Dr. Liebich, boost the market growth.

Recent Legalization Process of Cannabis in Germany

In October 2022, Health Minister of Germany, Karl Lauterbach, unveiled plans to legalize the possession of cannabis up to 30 grams. However, those plans were later scaled back following opposition from the European Union’s executive commission. Recently, in February 2024, the lower house of parliament (Bundestag) in Germany approved new legislation to legalize the limited recreational use of cannabis. As per the new rules, adults can possess a small quantity of cannabis for personal use, though the drug remains prohibited for individuals under the age of 18. The bill was passed with 407 lawmakers voting in favor of it, 226 voted against it, and four lawmakers abstained from voting. This move follows a controversial national debate about the advantages and disadvantages of making it easier to access the drug.

On April 1, 2024, Germany implemented one of the continent's most liberal cannabis laws by introducing the Cannabis Act. This new legislation permits adults to possess up to 25 grams of cannabis for personal use, store up to 50 grams at home, and allow the cultivation of up to three marijuana plants for personal consumption at home. In addition, starting July 1, individuals can legally purchase cannabis through "cannabis clubs" throughout the country.

The proposed law allows for the sale of marijuana through "cannabis social clubs." However, members of these clubs would not be permitted to consume it on the premises or within a 200-meter radius of the clubs. These clubs would be limited to 500 members and not allowed within 200 meters of any daycare center or school.

Key Takeaways

Regulatory Foundations & Market Growth

• The Cannabis Act (CanG) took effect on 1 April 2024, legalizing adult-use cannabis: 25 g possession in public, 50 g at home, and up to 3 home-grown plants. Cannabis Social Clubs (CSCs) became legal from 1 July 2024, limited to 500 members each.

Medical Cannabis Boom

• Medical patient numbers increased from ~250,000 in April 2024 to ~900,000 by May 2025-a nearly 4× increase in just over a year. Germany may surpass Florida to become the world's largest medical cannabis market by mid-2025, potentially reaching 1.5 million patients by end-2025.

Supply Chain & Import Trends

• Import volumes surged: from ~31.4 tons in 2023 to 70 tons in 2024, more than doubling in one year.

• Q2 2025 alone saw 43.3 tons imported, a 15% quarter-on-quarter increase, totaling 134 tons annually making Germany the world’s largest medical cannabis importer.

Market Concentration & Characteristics

The Germany legal cannabis market is characterized by a high degree of innovation owing to rising R&D activities on the use of cannabis and its medicinal properties, recent legalization activities, innovative cultivation technologies and growing demand for CBD-infused products. For instance, in August 2023, researchers from the Friedrich Schiller University Jena collaborated with colleagues from Austria, Italy, and the U.S. and identified anti-inflammatory effects shown by CBD.

Through M&A activity, these companies can expand their product portfolio, enter new territories, and strengthen their market position. For instance, in August 2023, SynBiotic SE, a Munich-based cannabis company, acquired CannaCare Health GmbH and its popular CBD brand, Canobo, to expand its product portfolio.

The cannabis industry in Germany is growing due to recent changes in regulations and the legalization by the lower house parliament. The legalization framework in Germany prioritizes public health goals and permits commercial production and distribution of cannabis, which contributes to the growth of the market in the country. The Federal Institute for Drugs and Medical Devices oversees the production and importation of cannabis in Germany.

Market players are adopting various strategies such as new product launch, partnerships & collaborations and distribution agreement to strengthen their market position. For instance, in January 2023, Ambari Brands Inc., a CBD product manufacturer, expanded its European distribution by selling its CBD products in almost every European country. The company will expand into France, Germany, Portugal, and Nordic Countries.

The popularity of CBD-infused foods is rapidly rising due to the various health benefits associated with CBD some market players are expanding their market presence in different geographical areas. For instance, in May 2022, Aurora Cannabis announced that its medical cannabis manufacturing units have received EU-GMP certification. This will allow the company to distribute the highest quality and premium medical cannabis in Germany.

Source Insights

The hemp segment dominated the market with the largest revenue share of 74.68% in 2024. Hemp covers an extensive range of products, including supplements, nutritional powders, beverages, protein & nutrition bars, animal feed, and pet food. Improving lifestyles and rising product launches drive the demand for hemp products. For instance, in April 2021, PepsiCo, a food and beverage company, launched Rockstar Energy + Hemp (a hemp beverage) in Germany. This drink contains hemp seed extract with guarana, ginseng, caffeine, B vitamins, taurine, and sugar.

Hemp has many uses in commercial products, such as animal feed, food, paper, textiles, biodegradable plastics, clothing, insulation, paint, and construction material. Its stems are used for different purposes - larger pieces are utilized for fibers, while smaller pieces (hurds or shives) are used in products ranging from insulation to pet bedding. The seeds are mainly used to extract oils, animal feed, flour, protein powder, and food ingredients. The leaves and flowers serve multiple purposes, such as tea, compost, and animal bedding.

The marijuana segment is anticipated to grow at a significant CAGR over the forecast period. The demand for marijuana in Germany is expected to increase due to rising awareness about its therapeutic benefits and recent changes in legalization. It has been used in cases of treating Alzheimer’s, multiple sclerosis, rheumatism, cancer, and AIDS, among other diseases. For instance, in May 2023, Village Farms International, Inc. launched cannabis products in Germany. The company launched the products in partnership with IUVO Therapeutics GmbH, a distributor of medical cannabis in the German market.

Derivatives Insights

The CBD segment dominated the market with the largest revenue share of 66.46% in 2024. CBD is the non-psychoactive compound found in the cannabis plant, and its adoption is increasing for a wide range of health benefits. Ongoing studies signify the potential benefits of CBD on certain health conditions, further driving the market growth. For instance, the study published in the Journal of British Journal of Cancer in March 2022, funded by the German Research Foundation, reported that CBD functions as antimetastatic and anti-angiogenic tumor therapy and supports the immune system's defense against tumors.

The others segment is expected to grow at fastest CAGR over the forecast period. The other segment includes derivatives or components of the cannabis plant, such as flavonoids, terpenes, and other minor cannabinoids. Factors such as growing adoption of minor cannabinoids, product launches, and adoption of various strategies for its distribution are anticipated to propel the segment growth. For instance, in August 2020, Avicanna Inc. advanced its supply chain business with commercial exports of CBD and CBG isolates in Germany and the U.S.

End Use Insights

The medical segment dominated the market with a revenue share of 73.30% in 2024, driven by the country’s progressive regulations that allow patients with chronic and severe health conditions to access cannabis-based treatments. Physicians in Germany are authorized to prescribe medical cannabis for conditions such as chronic pain, multiple sclerosis, epilepsy, and the side effects of chemotherapy, among others. This has led to a steady rise in patient adoption and has created a structured framework for cannabis as part of mainstream medical care. The growing acceptance of cannabis in therapeutic applications is also supported by increasing clinical evidence highlighting its efficacy in symptom management and quality-of-life improvement for patients.

The recreational use segment is expected to grow at the fastest CAGR over the forecast period. This segment primarily involves the use of cannabis for smoking or consuming it in the form of foods, edibles, and beverages. In addition, the legalization of cannabis for recreational purposes is contributing to the segment growth. For instance, in April 2024, Germany legalizes cannabis possession for personal use. Moreover, growing investment due to the liberalization of cannabis-related laws fuels market growth. For instance, in June 2024, Organigram Holdings Inc., a licensed cannabis producer and manufacturer of recreational products, invested USD 15.91 million in Sanity Group, a German company. The Company's investment expands the previously declared supply agreement between Organigram and Sanity Group.

Key Germany Legal Cannabis Company Insights

Key participants in the market are focusing on devising innovative business growth strategies in the form of product portfolio expansions, partnerships & collaborations, mergers & acquisitions, and business footprint expansions.

Competition & Strategic Moves

• International Expansion: Canadian and North American companies enter via joint ventures, acquisitions, and partnerships with local players to access distribution and EU-GMP facilities.

• Domestic Investment: German companies (e.g., DEMECAN, Cansativa, Four 20 Pharma, Avextra) focus on local cultivation, regulatory expertise, and supply chain strength to build market share.

• M&A Activity: Mergers and acquisitions accelerate market consolidation, scale, and distribution reach. Major deals bolster product portfolios and supply assurance.

• Partnerships: Collaborations with growers, pharma, and research groups drive innovation, clinical validation, and maintain quality standards.

• Tech & Digital: Investment in smart cultivation, AI, digital engagement, and telemedicine enhance operations and patient experience. New digital workflows increase efficiency.

Some examples include

• Tilray secured Germany's first cultivation license under MedCanG in mid-2024 and launched locally produced medical cannabis products-significantly expanding its production footprint.

• Aurora Cannabis received expanded cultivation and R&D licenses in 2024. Their local brand IndiMed, launched January 2025, is cultivated in Germany’s EU-GMP-certified facility.

• Curaleaf had earlier acquired a majority stake in Four 20 Pharma (2022), positioning itself strongly ahead of legalization.

Recent Developments

• In January 2025, Aurora Cannabis, a Canadian company, launched IndiMed, marking the introduction of the first medical cannabis product cultivated in Germany. This product is produced at Aurora’s EU-GMP facility in Leuna, Germany. The first offering from the IndiMed brand is Island Sweet Skunk, a dried flower with less than 1% CBD. The sativa variety contains 20% THC.

• In January 2025, High Tide Inc., a Canadian firm, reported its entry into the rapidly expanding German medical cannabis market by signing a definitive agreement to acquire a 51% stake in Purecan GmbH (Purecan) for approximately USD 5.45 million. Purecan is an import-focused pharmaceutical wholesaler located in Germany. It holds a license to import medical cannabis into the country.

• In May 2023, Stenocare, a Danish company, expanded into Germany with the launch of Medical Cannabis Oils in collaboration with ADREX Pharma, which specializes in developing, producing, and marketing medical cannabis products.

Germany Legal Cannabis Market Report Scope

Germany Legal Cannabis Market Report Segmentation

This report forecasts revenue growth and provides at country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Germany legal cannabis market report based on source, derivatives, and end use:

• Source Outlook (Revenue, USD Million, 2021 - 2033)

  • .Hemp

    • Hemp oil

    • Industrial Hemp

  • Marijuana

    • Flower

    • Oil and Tinctures

• Derivatives Outlook (Revenue, USD Million, 2021 - 2033)

  • CBD

  • THC

  • Others

• End Use Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Industrial Use

  • Medical Use

    • Chronic Pain

    • Depression and Anxiety

    • Arthritis

    • Post Traumatic Stress Disorder (PTSD)

    • Cancer

    • Migraines

    • Epilepsy

    • Alzheimers's

    • Multiple Sclerosis

    • AIDS

    • Amyotrophic Lateral Sclerosis

    • Tourettes

    • Diabetes

    • Parkinson's

    • Glaucoma

    • Others

  • Recreational Use